2011
MicroRNA let-7a: A potential marker for selection of paclitaxel in ovarian cancer management
Lu L, Schwartz P, Scarampi L, Rutherford T, Canuto EM, Yu H, Katsaros D. MicroRNA let-7a: A potential marker for selection of paclitaxel in ovarian cancer management. Gynecologic Oncology 2011, 122: 366-371. PMID: 21571355, DOI: 10.1016/j.ygyno.2011.04.033.Peer-Reviewed Original ResearchConceptsLow let-7aDisease progressionLet-7aSurvival analysisEpithelial ovarian cancer patientsPlatinum-based chemotherapyOvarian cancer managementOvarian cancer patientsAddition of paclitaxelType of treatmentLet-7a expressionOvarian cancer resistanceOverall survivalDifferent chemotherapyEOC patientsPatient survivalSurvival outcomesDisease stageOvarian tumorsCancer patientsTumor gradeDisease outcomeCancer managementBetter survivalEOC survival
2010
IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics.
Qian B, Katsaros D, Lu L, Canuto EM, Benedetto C, Beeghly-Fadiel A, Yu H. IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics. Oncology Reports 2010, 25: 203-13. PMID: 21109978, PMCID: PMC3075064, DOI: 10.3892/or_00001062.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overDisease-Free SurvivalDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor IIMiddle AgedNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPromoter Regions, GeneticReverse Transcriptase Polymerase Chain ReactionConceptsInsulin-like growth factor IIEpithelial ovarian cancerOvarian cancerDisease progressionResidual tumor sizeIGF-II peptideFresh tumor samplesIGF-II expressionPromoter-specific expressionIGF-II mRNAGrowth factor IIIGF-II promotersLower mRNA expressionOverall survivalAggressive diseasePoor prognosisTumor sizeDisease characteristicsMethylation-specific PCRTumor gradeTreatment responseIGF-II transcriptionPromoter-specific methylationClinical implicationsCancer
2008
High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1
Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Research And Treatment 2008, 117: 131-140. PMID: 18932017, DOI: 10.1007/s10549-008-0219-7.Peer-Reviewed Original ResearchConceptsMiR-21 expressionPoor disease-free survivalHigh miR-21 expressionDisease-free survivalHormone receptor statusHigh miR-21Breast cancerMiR-21Tumor samplesReceptor statusTumor gradeTGF-β1Elevated miR-21 expressionNegative hormone receptor statusProportional hazards regression analysisHigher TGF-β1Lymph node involvementEarly-stage diseaseEarly-stage patientsPrimary breast cancerHazards regression analysisHigh tumor gradeFresh tumor samplesTumor cell growthNode involvement